Design, Synthesis, and Evaluation of 18F‑Labeled Monoacylglycerol Lipase Inhibitors as Novel Positron Emission Tomography Probes

Dysfunction of monoacylglycerol lipase (MAGL) is associated with several psychopathological disorders, including drug addiction and neurodegenerative diseases. Herein we design, synthesize, and evaluate several irreversible fluorine-containing MAGL inhibitors for positron emission tomography (PET) l...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2019-10, Vol.62 (19), p.8866-8872
Hauptverfasser: Chen, Zhen, Mori, Wakana, Fu, Hualong, Schafroth, Michael A, Hatori, Akiko, Shao, Tuo, Zhang, Genwei, Van, Richard S, Zhang, Yiding, Hu, Kuan, Fujinaga, Masayuki, Wang, Lu, Belov, Vasily, Ogasawara, Daisuke, Giffenig, Pilar, Deng, Xiaoyun, Rong, Jian, Yu, Qingzhen, Zhang, Xiaofei, Papisov, Mikhail I, Shao, Yihan, Collier, Thomas L, Ma, Jun-An, Cravatt, Benjamin F, Josephson, Lee, Zhang, Ming-Rong, Liang, Steven H
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Dysfunction of monoacylglycerol lipase (MAGL) is associated with several psychopathological disorders, including drug addiction and neurodegenerative diseases. Herein we design, synthesize, and evaluate several irreversible fluorine-containing MAGL inhibitors for positron emission tomography (PET) ligand development. Compound 6 (identified from a therapeutic agent) was advanced for 18F-labeling via a novel spirocyclic iodonium ylide (SCIDY) strategy, which demonstrated high brain permeability and excellent specific binding. This work supports further development of novel 18F-labeled MAGL PET probes.
ISSN:0022-2623
1520-4804
DOI:10.1021/acs.jmedchem.9b00936